Validated international prognostic index stratifies patients according to low, intermediate, high risk<\/p>\n<\/h3>\n
<\/b><\/p>\n
<\/b><\/p>\n
FRIDAY, Feb. 12, 2021 (HealthDay News) — The Burkitt lymphoma (BL) International Prognostic Index (BL-IPI) provides robust discrimination of survival and can be used for prognostication, according to a study published online Jan. 27 in the Journal of Clinical Oncology<\/em>.<\/p>\n Adam J. Olszewski, M.D., from the Warren Alpert Medical School of Brown University in Providence, Rhode Island, and colleagues derived the BL-IPI from real-word data from adult patients with BL treated with immunochemotherapy in the United States between 2009 and 2018. Candidate variables that showed the strongest prognostic association with progression-free survival (PFS) were identified.<\/p>\n The researchers found that factors with an independent prognostic value identified from the derivation cohort of 633 patients with BL were age \u00e2\u0089\u00a540 years, performance status \u00e2\u0089\u00a52, serum lactate dehydrogenase >3 times upper limit of normal, and central nervous system involvement. The resulting BL-IPI identified groups with low, intermediate, and high risk (zero, one, and two or more risk factors [18, 36, and 46 percent of patients, respectively]), with three-year PFS estimates of 92, 72, and 53 percent, respectively, and three-year overall survival estimates of 96, 76, and 59 percent, respectively. In the validation cohort of 457 patients, patient characteristics, size of BL-IPI groups, and outcome discrimination were consistent, with three-year PFS estimates of 96, 82, and 63 percent for low-, intermediate-, and high-risk BL-IPIs, respectively.<\/p>\n “This novel, validated index can help clinicians more accurately identify a prognosis for their adult Burkitt lymphoma patients, as well as advance targeted clinical research studies,” Olszewski said in a statement.<\/p>\n Several authors disclosed financial ties to the biopharmaceutical industry. <\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n